

Posting Date: August 5, 2020

Closing Date: August 14, 2020 11:30 a.m.

ET Reference Number: 20-035188

To: NCI Bid Board

From: Sharon Coles-Calloway
NCI DCEG Purchasing Agent
coless@mail.nih.gov

Subject: BID BOARD POSTING: Genotyping for expanded Female Lung Cancer Consortium in Asia: Japan

The Occupational and Environmental Epidemiology Branch (OEEB) conducts studies in the United States and abroad to identify and evaluate environmental and workplace exposures that may be associated with cancer risk. OEEB's mission is to combine epidemiology, quantitative exposure assessment, and molecular components into multi-disciplinary studies to provide insight into cancer etiology, chemical carcinogenesis, and mechanisms of action.

To understand the etiology of lung cancer in non-smoking Asian women, the NCI formed the Female Lung Cancer Consortium in Asia (FLCCA) and has conducted a genome-wide association study (GWAS) of lung cancer among never-smoking women and in collaboration with other studies in Asia including Japan have identified multiple novel loci. When NCI compared GWAS findings between Asians and populations of European descent published to date we have found only modest overlap in findings suggesting that certain lung cancer susceptibility loci may specific to Eastern Asian populations.

To further investigate NCI proposes to expand our previous GWAS by scanning an additional 10,000 cases and 3,000 controls from centers across East Asia, as well as obtaining GWAS data on 7,200 controls from other OEEB and extramural studies that were scanned using the same genotyping array from the National Cancer Center of Japan, Results from this expanded Tokyo, Japan. study will be combined via meta-analysis with those from our previous scans to yield the largest study of the genetic susceptibility to lung adenocarcinoma among never smokers anywhere in the world. This is not a request for competitive quotation. However, if any interested party believes it can meet the attached requirements, it may submit a statement of capabilities. The capability statement must be in writing and must contain information and material in sufficient detail to allow NCI to determine is the party can fully meet this requirement. The capability statement must be received in the contracting office by 11:30 AM on August 14, 2020 ET. A determination by the Government not to compete this requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement.

Sole Source Justification:

NCI did extensive literature searches (i.e. PubMed and Scopus), and discussed with scientists at national and international meetings, and the National Cancer Center (NCC) in Japan is the nation's leading cancer treatment, prevention, control, research and education program. It is the Japanese site of the Female Lung Cancer Consortium in Asia (FLCCA) and is the largest cancer research center in Japan. Working with its hospital centers, the division of genome biology of NCC has performed large scale genotyping for genome-wide association studies including collaborative studies with the NCI and published with NCI genetic risk factors for lung adenocarcinoma. It is critical for scientific comparability that new cases that will be genotyped in this procurement be comparable to cases that were genotyped previously by the same center in Japan in the initial NCI GWAS of lung cancer in Asia. There is no other contract able to provide this service.

Attached Documents:

SF18

Statement of Work

FAR 52.204-24 Representation Regarding Certain Telecommunications and Video Surveillance Services or Equipment.

FAR Clause 52.213-4 Simplified Acquisitions Terms and Conditions (AUG 2019) is applicable and available in full text upon request

REQUEST FOR QUOTATION (THIS IS NOT AN ORDER)	THIS RFQ <input checked="" type="checkbox"/> IS <input type="checkbox"/> IS NOT A SMALL BUSINESS SET-ASIDE	PAGE 1 OF 1 PAGES 1
---	--	---------------------

1. REQUEST NO.	2. DATE ISSUED 07/31/2020	3. REQUISITION/PURCHASE REQUEST NO. 20-035188	4. CERT. FOR NAT. DEF. UNDER BDSA REG. 2 AND/OR DMS REG. 1 RATING
----------------	------------------------------	--	--

5a. ISSUED BY NIH/NCI-CCR P-ARC	6. DELIVER BY (Date) 12 months after receipt of order
------------------------------------	--

5b. FOR INFORMATION CALL (NO COLLECT CALLS)		7. DELIVERY <input checked="" type="checkbox"/> FOB DESTINATION <input type="checkbox"/> OTHER (See Schedule)
---	--	--

NAME Sharon Coles-Calloway, Purchasing Agent	TELEPHONE NUMBER AREA CODE 240	NUMBER 276-7348	9. DESTINATION a. NAME OF CONSIGNEE
---	--------------------------------------	--------------------	--

8. TO:		b. STREET ADDRESS
a. NAME	b. COMPANY	c. CITY

c. STREET ADDRESS	c. CITY
-------------------	---------

d.. CITY	e.. STATE	f.. ZIP CODE	d.. STATE	e. ZIP CODE
----------	-----------	--------------	-----------	-------------

10. PLEASE FURNISH QUOTATIONS TO THE ISSUING OFFICE IN BLOCK 5a ON OR BEFORE CLOSE OF BUSINESS (Date) 8/13/2020 11:30 ET	IMPORTANT: This is a request for information, and quotations furnished are not offers. If you are unable to quote, please indicate on this form and return it to the address in Block 5a. This request does not commit the Government to pay any costs incurred in the preparation of the submission of this quotation or to contract for supplies or services. Supplies are of domestic origin unless otherwise indicated by quoter. Any representations and/or certifications attached to this Request for Quotations must be completed by the quoter.
---	---

11. SCHEDULE (Include applicable Federal, State and local taxes)

ITEM NO. (a)	SUPPLIES/SERVICES (b)	QUANTITY (c)	UNIT (d)	UNIT PRICE (e)	AMOUNT (f)
001	Genotyping for expanded Female Lung Cancer Consortium in Asia: Japan Notice of Intent: If submitting a capability statement, please e-mail only 1 copy of the technical capability statement to Sharon Coles-Calloway at coless@mail.nih.gov See attached statement of need. This will be awarded as a Firm-Fixed Price Contract.	1	ea	\$ _____	\$ _____

12. DISCOUNT FOR PROMPT PAYMENT	a. 10 CALENDAR DAYS (%)	b. 20 CALENDAR DAYS (%)	c. 30 CALENDAR DAYS (%)	d. CALENDAR DAYS NUMBER PERCENTAGE
---------------------------------	-------------------------	-------------------------	-------------------------	---

NOTE: Additional provisions and representations are are not attached.

13. NAME AND ADDRESS OF QUOTER	14. SIGNATURE OF PERSON AUTHORIZED TO SIGN QUOTATION	15. DATE OF QUOTATION
--------------------------------	--	-----------------------

a. NAME OF QUOTER	16. SIGNER	
-------------------	------------	--

b. STREET ADDRESS	a. NAME (Type or print)	b. TELEPHONE AREA CODE
-------------------	-------------------------	---------------------------

c. COUNTY	e. STATE	f. ZIP CODE	c. TITLE (Type or print)	NUMBER
-----------	----------	-------------	--------------------------	--------

STATEMENT OF WORK (SOW)

1.0 TITLE

Genotyping for expanded Female Lung Cancer Consortium in Asia: Japan (CAS: 10414)

2.0 BACKGROUND

Lung cancer is the leading cause of cancer mortality that accounted for 1.6 million deaths worldwide in 2012. Although smoking is the preeminent risk factor for lung cancer, approximately 25% of cases occur in non-smokers worldwide, with a substantially higher prevalence in Eastern and Southern Asia, particularly among women. To further understand the etiology of lung cancer in non-smoking Asian women, the NCI formed the Female Lung Cancer Consortium in Asia (FLCCA) and has conducted a genome-wide association study (GWAS) of lung cancer among never-smoking women and in collaboration with other studies in Asia including Japan have identified multiple novel loci. When we compared GWAS findings between Asians and populations of European descent published to date we have found only modest overlap in findings suggesting that certain lung cancer susceptibility loci may specific to Eastern Asian populations.

We previously conducted a genome wide association study (GWAS) that has uncovered genomic regions associated with genetic susceptibility that might be unique to East Asian female never smoker. We established the Female Lung Cancer Consortium in Asia (FLCCA) to facilitate this effort and worked with other GWAS in Japan and China. We identified 10 lung cancer susceptibility loci, including those on chromosomes 3q28, 5p15.33, 6p21.1, 6p21.32, 6q22.2, 9p21.3, 10q25.2 and 12q13.13. Although this study has shed light on the genetic underpinnings of lung cancer etiology, the susceptibility loci that were identified do not fully account for the genetic heritability of this malignancy. Many common and moderately uncommon susceptibility loci that contribute to lung cancer among never smokers remain unidentified, primarily due to the limited sample size of existing GWAS of lung cancer. To investigate further, we propose to expand our previous GWAS by scanning an additional 10,000 cases and 3,000 controls from centers across East Asia, as well as obtaining GWAS data on 7,200 controls from other OEEB and extramural studies that were scanned using the same genotyping array. Results from this expanded study will be combined via meta-analysis with those from our previous scans to yield the largest study of the genetic susceptibility to lung adenocarcinoma among never smokers anywhere in the world.

2.1 OBJECTIVE

The purpose of this procurement is to support whole-genome scanning 1000 DNA samples from never-smoking female lung adenocarcinoma cases in Japan using Illumina GSA SNP array chips provided by the NCI.

3.0 SCOPE

To genotype DNA samples from 1000 never-smoking lung adenocarcinoma cases. Prepare phenotype data including diagnosis, smoking status, age, and other demographic data based on a protocol to be provided by NCI and transfer the individual GWAS dataset and phenotype file to the NCI.

4.0 CONTRACT REQUIREMENTS/ AND PERSONNEL QUALIFICATIONS

STATEMENT OF WORK (SOW)

The Contractor shall perform the following tasks:

- 4.1 Extract and quantify 1000 DNA samples from never-smoking female lung adenocarcinoma cases and verify phenotype data regarding smoking status, gender and cancer diagnosis.
- 4.2 Scan 1000 DNA samples on disposable Illumina GSA SNP array chips that will be provided by the NCI.
- 4.3 Report issues in the analysis of samples to the NCI technical point of contact (POC) via email within three business days of occurrence.
- 4.4 Prepare phenotype data including confirmed diagnosis, smoking status, gender, age, etc. based on a protocol to be provided by NCI within 15 days of the award.
- 4.5 Upload GWAS raw data, summary data and phenotype data of 1000 scanned DNA samples to the Globus site set up by NCI (<https://hpc.nih.gov/storage/globus.html>).

5.0 TYPE OF ORDER

This is a firm fixed price purchase order.

6.0 PERIOD OF PERFORMANCE

The period of performance shall be September 21, 2020 to September 20, 2021.

7.0 PLACE OF PERFORMANCE

All work shall be performed at the Contractor's facility.

8.0 REPORT(S)/DELIVERABLES AND DELIVERY SCHEDULE

The contractor shall contact the NCI Project Officer monthly to report the number of samples processed. The contractor shall deliver the data to the NCI project officer no later than August 1, 2021.

9.0 PAYMENT

Payment shall be made once after the deliverables are made. Payment authorization requires submission and approval of invoices to the COR and NIH OFM, in accordance with the attached payment provisions listed below:

The following clause is applicable to all Purchase Orders, Task or Delivery Orders, and Blanket Purchase Agreement (BPA) Calls: PROMPT PAYMENT (JUL 2013) FAR 52.232-25. Highlights of this clause and NIH implementation requirements follow:

I INVOICE REQUIREMENTS

- A. An invoice is the Contractor's bill or written request for payment under the contract for supplies delivered or services performed. A proper invoice is an "Original" which must include the items listed in subdivisions 1 through 12, below, in addition to the requirements of FAR 32.9. If the invoice does not comply with these requirements, the Contractor will be

STATEMENT OF WORK (SOW)

notified of the defect within 7 days after the date the designated billing office received the invoice (3 days for meat, meat food products, or fish, and 5 days for perishable agricultural commodities, dairy products, edible fats or oils) with a statement of the reasons why it is not a proper invoice. (See exceptions under II., below.) Untimely notification will be taken into account in the computation of any interest penalty owed the Contractor.

1. Vendor/Contractor: Name, Address, Point of Contact for the invoice (Name, title, telephone number, e-mail and mailing address of point of contact).
2. Remit-to address (Name and complete mailing address to send payment).
3. Remittance name must match exactly with name on original order/contract. If the Remittance name differs from the Legal Business Name, then both names must appear on the invoice.
4. Invoice date.
5. Unique invoice #s for all invoices per vendor regardless of site.
6. NBS document number formats must be included for awards created in the NBS: Contract Number; Purchase Order Number; Task or Delivery Order Number and Source Award Number (e.g., Indefinite Delivery Contract number; General Services Administration number); or, BPA Call Number and BPA Parent Award Number.
7. Data Universal Numbering System (DUNS) or DUNS + 4 as registered in the Central Contractor Registration (CCR).
8. Federal Taxpayer Identification Number (TIN). In those exceptional cases where a contractor does not have a DUNS number or TIN, a Vendor Identification Number (VIN) must be referenced on the invoice. The VIN is the number that appears after the contractor's name on the face page of the award document.
9. Identify that payment is to be made using a three-way match.
10. Description of supplies/services that match the description on the award, by line billed.*
11. Freight or delivery charge must be billed as shown on the award. If it is included in the item price do not bill it separately. If identified in the award as a separate line item, it must be billed separately.
12. Quantity, Unit of Measure, Unit Price, Extended Price of supplies delivered or services performed, as applicable, and that match the line items specified in the award.*

* NOTE: If your invoice must differ from the line items on the award, please contact the Contracting Officer before submitting the invoice. A modification to the order or contract may be needed before the invoice can be submitted and paid.

B. Shipping costs will be reimbursed only if authorized by the Contract/Purchase Order. If authorized, shipping costs must be itemized. Where shipping costs exceed \$100, the invoice must be supported by a bill of lading or a paid carrier's receipt.

C. Mail an original and 1 copy of the itemized invoice to:

National Institutes of Health
Office of Financial Management, Commercial Accounts
2115 East Jefferson Street, Room 4B-432, MSC 8500
Bethesda, MD 20892-8500

For inquiries regarding payment call: (301) 496-6088

STATEMENT OF WORK (SOW)

In order to facilitate the prompt payment of invoices, it is recommended that the vendor submit a photocopy of the invoice to the “Consignee” designated for the acquisition in blocks 6A – 6E of the face page of the Order/Award document.

II. INVOICE PAYMENT

- A. Except as indicated in paragraph B., below, the due date for making invoice payments by the designated payment office shall be the later of the following two events:
 - 1. The 30th day after the designated billing office has received a proper invoice.
 - 2. The 30th day after Government acceptance of supplies delivered or services performed.
- B. The due date for making invoice payments for meat and meat food products, perishable agricultural commodities, dairy products, and edible fats or oils, shall be in accordance with the Prompt Payment Act, as amended.

III. INTEREST PENALTIES

- A. An interest penalty shall be paid automatically, if payment is not made by the due date and the conditions listed below are met, if applicable.
 - 1. A proper invoice was received by the designated billing office.
 - 2. A receiving report or other Government documentation authorizing payment was processed and there was no disagreement over quantity, quality, or contractor compliance with a term or condition.
 - 3. In the case of a final invoice for any balance of funds due the contractor for supplies delivered or services performed, the amount was not subject to further settlement actions between the Government and the Contractor.
- B. Determination of interest and penalties due will be made in accordance with the provisions of the Prompt Payment Act, as amended, the Contract Disputes Act, and regulations issued by the Office of Management and Budget.

IV. PROVIDING ACCELERATED PAYMENT TO SMALL BUSINESS SUBCONTRACTORS, FAR 52.232-40 (DEC 2013)

- a) Upon receipt of accelerated payments from the Government, the Contractor shall make accelerated payments to its small business subcontractors under this contract, to the maximum extent practicable and prior to when such payment is otherwise required under the applicable contract or subcontract, after receipt of a proper invoice and all other required documentation from the small business subcontractor.
- b) The acceleration of payments under this clause does not provide any new rights under the prompt Payment Act.

Include the substance of this clause, include this paragraph c, in all subcontracts with small business concerns, including subcontracts with small business concerns for the acquisition of commercial items.

52.204-24 Representation Regarding Certain Telecommunications and Video Surveillance Services or Equipment.

As prescribed in 4.2105(a), insert the following provision:

REPRESENTATION REGARDING CERTAIN TELECOMMUNICATIONS AND VIDEO SURVEILLANCE SERVICES OR EQUIPMENT (AUG 2019)

(a) Definitions. As used in this provision—

Covered telecommunications equipment or services, Critical technology, and Substantial or essential component have the meanings provided in clause 52.204-25, Prohibition on Contracting for Certain Telecommunications and Video Surveillance Services or Equipment.

(b) Prohibition. Section 889(a)(1)(A) of the John S. McCain National Defense Authorization Act for Fiscal Year 2019 (Pub. L. 115-232) prohibits the head of an executive agency on or after August 13, 2019, from procuring or obtaining, or extending or renewing a contract to procure or obtain, any equipment, system, or service that uses covered telecommunications equipment or services as a substantial or essential component of any system, or as critical technology as part of any system. Contractors are not prohibited from providing—

(1) A service that connects to the facilities of a third-party, such as backhaul, roaming, or interconnection arrangements; or

(2) Telecommunications equipment that cannot route or redirect user data traffic or permit visibility into any user data or packets that such equipment transmits or otherwise handles.

(c) Representation. The Offeror represents that—

It [] will, [] will not provide covered telecommunications equipment or services to the Government in the performance of any contract, subcontract or other contractual instrument resulting from this solicitation.

(d) Disclosures. If the Offeror has responded affirmatively to the representation in paragraph (c) of this provision, the Offeror shall provide the following information as part of the offer—

(1) All covered telecommunications equipment and services offered (include brand; model number, such as original equipment manufacturer (OEM) number, manufacturer part number, or wholesaler number; and item description, as applicable);

(2) Explanation of the proposed use of covered telecommunications equipment and services and any factors relevant to determining if such use would be permissible under the prohibition in paragraph (b) of this provision;

(3) For services, the entity providing the covered telecommunications services (include entity name, unique entity identifier, and Commercial and Government Entity (CAGE) code, if known); and

(4) For equipment, the entity that produced the covered telecommunications equipment (include entity name, unique entity identifier, CAGE code, and whether the entity was the OEM or a distributor, if known).

(End of provision)